Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development
Patients with <i>EGFR</i>-mutated NSCLC are prone to developing Type I LM. Osimertinib for <i>EGFR</i>-mutated cases and ICIs are expected to prevent Type I LM after the diagnosis of BMs.
Authors
- Yuzo Hasegawa (ORCID: https://orcid.org/0000-0001-5816-2836)
- Junji Hosono (ORCID: https://orcid.org/0000-0003-3944-7590)
- Masato Shingyoji
- Toshihiko Iuchi (ORCID: https://orcid.org/0000-0002-4933-0049)
- Taiki Setoguchi
- Hironori Ashinuma (ORCID: https://orcid.org/0000-0002-5277-5233)
- Tsukasa Sakaida
- Satoko Mizuno
Institutions
- Chiba Cancer Center (JP)
Publication Details
- Journal
- Neuro-Oncology Practice
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1093/nop/npae118
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Japan Society for the Promotion of Science